There are currently 665 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Aurora St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Parkinson's Disease
Exercise Training in Children With Communication Impairments
Recruiting
This clinical trial study has two goals. The first goal is to establish fitness levels, participation in physical activities, and fine/gross motor abilities for children with development language disorder (DLD). DLD occurs in 1/13 children and children with DLD often have poorer fine/gross motor skills than those with typical development. The second goal is to determine whether physical exercise helps children with DLD and typical development to learn better and improve fitness and fine/gross mo... Read More
Gender:
ALL
Ages:
Between 5 years and 9 years
Trial Updated:
05/16/2025
Locations: Marquette U, Milwaukee, Wisconsin
Conditions: Developmental Language Disorder
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
Recruiting
The study design is an observational cohort study of patients undergoing standard of care oral cavity reconstruction. An observational study is required to prospectively evaluate microbial and antibiotic mechanisms underlying surgical site infection after oral cavity reconstruction.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/16/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Oral Cancer
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Recruiting
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Malignant Solid Neoplasm
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
05/15/2025
Locations: Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin +3 locations
Conditions: Ovarian Carcinoma
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/15/2025
Locations: Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
Recruiting
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC V8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC V8
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Froedert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients
Recruiting
Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube aga... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Obesity, Morbid, Extubation Failure
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
Recruiting
This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Froedtert and Medical College of Wisconsin - Milwaukee, Milwaukee, Wisconsin
Conditions: Spasticity, Cerebral or Spinal Condition